Shattuck Labs (STTK) Competitors

$6.67 -0.08 (-1.19%)

Closing price 04:00 PM Eastern

Extended Trading

$6.68 +0.01 (+0.22%)

As of 04:11 PM Eastern

STTK vs. ZYME, GENB, PHVS, CAPR, and ANIP

Should you buy Shattuck Labs stock or one of its competitors? MarketBeat compares Shattuck Labs with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Shattuck Labs include Zymeworks (ZYME), Generate Biomedicines (GENB), Pharvaris (PHVS), Capricor Therapeutics (CAPR), and ANI Pharmaceuticals (ANIP). These companies are all part of the "pharmaceutical products" industry.

How does Shattuck Labs compare to Zymeworks?

Shattuck Labs (NASDAQ:STTK) and Zymeworks (NASDAQ:ZYME) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, media sentiment, dividends, valuation, analyst recommendations and profitability.

In the previous week, Zymeworks had 19 more articles in the media than Shattuck Labs. MarketBeat recorded 24 mentions for Zymeworks and 5 mentions for Shattuck Labs. Shattuck Labs' average media sentiment score of 1.04 beat Zymeworks' score of 0.16 indicating that Shattuck Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Shattuck Labs	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Zymeworks	1 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

58.7% of Shattuck Labs shares are held by institutional investors. Comparatively, 92.9% of Zymeworks shares are held by institutional investors. 8.8% of Shattuck Labs shares are held by insiders. Comparatively, 33.5% of Zymeworks shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Shattuck Labs has higher earnings, but lower revenue than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Shattuck Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$1M	511.46	-$48.81M	-$0.63	N/A
Zymeworks	$81.26M	21.53	-$81.13M	-$1.37	N/A

Shattuck Labs has a beta of 1.18, indicating that its share price is 18% more volatile than the broader market. Comparatively, Zymeworks has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market.

Shattuck Labs has a net margin of 0.00% compared to Zymeworks' net margin of -126.92%. Zymeworks' return on equity of -37.97% beat Shattuck Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-60.73%	-55.75%
Zymeworks	-126.92%	-37.97%	-25.31%

Shattuck Labs presently has a consensus target price of $13.00, suggesting a potential upside of 94.90%. Zymeworks has a consensus target price of $38.00, suggesting a potential upside of 58.60%. Given Shattuck Labs' higher probable upside, equities research analysts clearly believe Shattuck Labs is more favorable than Zymeworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.92

Summary

Zymeworks beats Shattuck Labs on 10 of the 17 factors compared between the two stocks.

How does Shattuck Labs compare to Generate Biomedicines?

Shattuck Labs (NASDAQ:STTK) and Generate Biomedicines (NASDAQ:GENB) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership.

Generate Biomedicines has higher revenue and earnings than Shattuck Labs.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$1M	511.46	-$48.81M	-$0.63	N/A
Generate Biomedicines	$30.30M	65.45	N/A	N/A	N/A

58.7% of Shattuck Labs shares are owned by institutional investors. 8.8% of Shattuck Labs shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Generate Biomedicines had 10 more articles in the media than Shattuck Labs. MarketBeat recorded 15 mentions for Generate Biomedicines and 5 mentions for Shattuck Labs. Shattuck Labs' average media sentiment score of 1.04 beat Generate Biomedicines' score of -0.29 indicating that Shattuck Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Shattuck Labs	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Generate Biomedicines	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Shattuck Labs currently has a consensus target price of $13.00, suggesting a potential upside of 94.90%. Generate Biomedicines has a consensus target price of $25.40, suggesting a potential upside of 64.19%. Given Shattuck Labs' higher probable upside, analysts clearly believe Shattuck Labs is more favorable than Generate Biomedicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Generate Biomedicines	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

Generate Biomedicines' return on equity of 0.00% beat Shattuck Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-60.73%	-55.75%
Generate Biomedicines	N/A	N/A	N/A

Summary

Shattuck Labs beats Generate Biomedicines on 6 of the 11 factors compared between the two stocks.

How does Shattuck Labs compare to Pharvaris?

Shattuck Labs (NASDAQ:STTK) and Pharvaris (NASDAQ:PHVS) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.

In the previous week, Pharvaris had 8 more articles in the media than Shattuck Labs. MarketBeat recorded 13 mentions for Pharvaris and 5 mentions for Shattuck Labs. Shattuck Labs' average media sentiment score of 1.04 beat Pharvaris' score of 0.58 indicating that Shattuck Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Shattuck Labs	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Pharvaris	1 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Shattuck Labs' return on equity of -60.73% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-60.73%	-55.75%
Pharvaris	N/A	-66.58%	-60.15%

Shattuck Labs has higher revenue and earnings than Pharvaris. Shattuck Labs is trading at a lower price-to-earnings ratio than Pharvaris, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$1M	511.46	-$48.81M	-$0.63	N/A
Pharvaris	N/A	N/A	-$198.79M	-$3.37	N/A

Shattuck Labs currently has a consensus target price of $13.00, indicating a potential upside of 94.90%. Pharvaris has a consensus target price of $49.18, indicating a potential upside of 60.20%. Given Shattuck Labs' higher possible upside, equities analysts clearly believe Shattuck Labs is more favorable than Pharvaris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Pharvaris	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

58.7% of Shattuck Labs shares are owned by institutional investors. 8.8% of Shattuck Labs shares are owned by insiders. Comparatively, 11.8% of Pharvaris shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Shattuck Labs has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market. Comparatively, Pharvaris has a beta of -2.34, meaning that its share price is 334% less volatile than the broader market.

Summary

Shattuck Labs beats Pharvaris on 9 of the 14 factors compared between the two stocks.

How does Shattuck Labs compare to Capricor Therapeutics?

Shattuck Labs (NASDAQ:STTK) and Capricor Therapeutics (NASDAQ:CAPR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.

Shattuck Labs has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market. Comparatively, Capricor Therapeutics has a beta of 0.48, meaning that its share price is 52% less volatile than the broader market.

Shattuck Labs has higher revenue and earnings than Capricor Therapeutics. Capricor Therapeutics is trading at a lower price-to-earnings ratio than Shattuck Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$1M	511.46	-$48.81M	-$0.63	N/A
Capricor Therapeutics	N/A	N/A	-$105.04M	-$2.32	N/A

58.7% of Shattuck Labs shares are owned by institutional investors. Comparatively, 21.7% of Capricor Therapeutics shares are owned by institutional investors. 8.8% of Shattuck Labs shares are owned by insiders. Comparatively, 9.2% of Capricor Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Capricor Therapeutics had 15 more articles in the media than Shattuck Labs. MarketBeat recorded 20 mentions for Capricor Therapeutics and 5 mentions for Shattuck Labs. Shattuck Labs' average media sentiment score of 1.04 beat Capricor Therapeutics' score of 0.12 indicating that Shattuck Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Shattuck Labs	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Capricor Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral

Shattuck Labs' return on equity of -60.73% beat Capricor Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-60.73%	-55.75%
Capricor Therapeutics	N/A	-69.50%	-55.81%

Shattuck Labs currently has a consensus target price of $13.00, indicating a potential upside of 94.90%. Capricor Therapeutics has a consensus target price of $46.09, indicating a potential upside of 54.62%. Given Shattuck Labs' higher possible upside, equities analysts clearly believe Shattuck Labs is more favorable than Capricor Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Capricor Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Summary

Shattuck Labs beats Capricor Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Shattuck Labs compare to ANI Pharmaceuticals?

ANI Pharmaceuticals (NASDAQ:ANIP) and Shattuck Labs (NASDAQ:STTK) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, media sentiment, risk, valuation and earnings.

ANI Pharmaceuticals currently has a consensus price target of $107.33, suggesting a potential upside of 34.87%. Shattuck Labs has a consensus price target of $13.00, suggesting a potential upside of 94.90%. Given Shattuck Labs' higher probable upside, analysts clearly believe Shattuck Labs is more favorable than ANI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ANI Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.88
Shattuck Labs	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

ANI Pharmaceuticals has higher revenue and earnings than Shattuck Labs. Shattuck Labs is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANI Pharmaceuticals	$883.37M	2.02	$78.34M	$3.95	20.15
Shattuck Labs	$1M	511.46	-$48.81M	-$0.63	N/A

In the previous week, ANI Pharmaceuticals had 22 more articles in the media than Shattuck Labs. MarketBeat recorded 27 mentions for ANI Pharmaceuticals and 5 mentions for Shattuck Labs. Shattuck Labs' average media sentiment score of 1.04 beat ANI Pharmaceuticals' score of 0.30 indicating that Shattuck Labs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ANI Pharmaceuticals	8 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Shattuck Labs	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

76.1% of ANI Pharmaceuticals shares are owned by institutional investors. Comparatively, 58.7% of Shattuck Labs shares are owned by institutional investors. 8.1% of ANI Pharmaceuticals shares are owned by company insiders. Comparatively, 8.8% of Shattuck Labs shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

ANI Pharmaceuticals has a net margin of 9.98% compared to Shattuck Labs' net margin of 0.00%. ANI Pharmaceuticals' return on equity of 27.51% beat Shattuck Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ANI Pharmaceuticals	9.98%	27.51%	10.02%
Shattuck Labs	N/A	-60.73%	-55.75%

ANI Pharmaceuticals has a beta of 0.46, suggesting that its stock price is 54% less volatile than the broader market. Comparatively, Shattuck Labs has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market.

Summary

ANI Pharmaceuticals beats Shattuck Labs on 11 of the 17 factors compared between the two stocks.

Get Shattuck Labs News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

STTK vs. The Competition

Export

Metric	Shattuck Labs	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$511.46M	$3.40B	$6.29B	$12.46B
Dividend Yield	N/A	2.31%	2.79%	5.30%
P/E Ratio	-10.59	18.81	20.87	25.58
Price / Sales	511.46	181.67	521.63	63.56
Price / Cash	N/A	122.51	42.94	55.34
Price / Book	5.34	6.74	9.86	6.70
Net Income	-$48.81M	$24.11M	$3.55B	$333.77M
7 Day Performance	6.55%	0.07%	-0.32%	0.45%
1 Month Performance	-1.62%	0.84%	1.34%	4.06%
1 Year Performance	636.94%	78.10%	41.03%	36.21%

Shattuck Labs Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
STTK Shattuck Labs	3.3893 of 5 stars	$6.67 -1.2%	$13.00 +94.9%	+602.7%	$511.46M	$1M	N/A	100	Positive News Earnings Report
ZYME Zymeworks	3.1804 of 5 stars	$26.68 -0.4%	$37.89 +42.0%	N/A	$1.97B	$105.97M	N/A	460	News Coverage Earnings Report Analyst Revision
GENB Generate Biomedicines	N/A	$15.42 +6.6%	$23.20 +50.5%	N/A	$1.97B	$31.89M	N/A	312	Earnings Report Analyst Forecast Analyst Revision
PHVS Pharvaris	3.8845 of 5 stars	$30.02 flat	$42.73 +42.3%	+104.5%	$1.96B	N/A	N/A	30	Analyst Forecast High Trading Volume
CAPR Capricor Therapeutics	2.2948 of 5 stars	$32.96 -1.6%	$46.09 +39.8%	+315.5%	$1.91B	N/A	N/A	101	Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:STTK) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Shattuck Labs (STTK) Competitors

STTK vs. ZYME, GENB, PHVS, CAPR, and ANIP

How does Shattuck Labs compare to Zymeworks?

Summary

How does Shattuck Labs compare to Generate Biomedicines?

Summary

How does Shattuck Labs compare to Pharvaris?

Summary

How does Shattuck Labs compare to Capricor Therapeutics?

Summary

How does Shattuck Labs compare to ANI Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STTK vs. The Competition

Shattuck Labs Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Shattuck Labs (STTK) Competitors

STTK vs. ZYME, GENB, PHVS, CAPR, and ANIP

How does Shattuck Labs compare to Zymeworks?

Does the media favor STTK or ZYME?

Do insiders and institutionals have more ownership in STTK or ZYME?

Which has higher valuation & earnings, STTK or ZYME?

Which has more volatility & risk, STTK or ZYME?

Is STTK or ZYME more profitable?

Do analysts prefer STTK or ZYME?

Summary

How does Shattuck Labs compare to Generate Biomedicines?

Which has better earnings and valuation, STTK or GENB?

Do institutionals and insiders hold more shares of STTK or GENB?

Does the media prefer STTK or GENB?

Do analysts recommend STTK or GENB?

Is STTK or GENB more profitable?

Summary

How does Shattuck Labs compare to Pharvaris?

Does the media refer more to STTK or PHVS?

Is STTK or PHVS more profitable?

Which has preferable valuation and earnings, STTK or PHVS?

Do analysts recommend STTK or PHVS?

Do institutionals & insiders believe in STTK or PHVS?

Which has more volatility and risk, STTK or PHVS?

Summary

How does Shattuck Labs compare to Capricor Therapeutics?

Which has more volatility and risk, STTK or CAPR?

Which has preferable valuation and earnings, STTK or CAPR?

Do institutionals & insiders believe in STTK or CAPR?

Does the media refer more to STTK or CAPR?

Is STTK or CAPR more profitable?

Do analysts recommend STTK or CAPR?

Summary

How does Shattuck Labs compare to ANI Pharmaceuticals?

Do analysts prefer ANIP or STTK?

Which has higher valuation & earnings, ANIP or STTK?

Does the media refer more to ANIP or STTK?

Do institutionals & insiders have more ownership in ANIP or STTK?

Is ANIP or STTK more profitable?

Which has more volatility & risk, ANIP or STTK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STTK vs. The Competition

Shattuck Labs Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools